Canvax Releases New Inorganic Pyrophosphate

News
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter, September 2022
Volume 17
Issue 9

Canvax’s new inorganic pyrophosphate is designed for in-vitro transcription reactions.

Canvax, a European supplier of enzymes, recombinant proteins, and similar products, announced the release of a new inorganic pyrophosphate on Aug. 25, 2022. The new enzyme, isolated from E. coli, is a DNA replication enhancer with ≥ 95% purity and has an enhanced capacity for increasing RNA yield in in-vitro transcription (IVT) reactions.

The enzyme has been stable under temperatures below 80º and is free of endonucleases, exonucleases, and RNAses. According to a company press release, this makes it ideal for use in RNA IVT reactions because it can reduce the inhibitory effects of protein-protein interactions. The company also stated in the release that it is suitable for messenger RNA-based vaccine manufacturing, RNA labeling, and enhancement of DNA replication.

“We're glad to contribute with this new launch, significantly to supporting mRNA vaccines manufacturing, and we're pleased that the research community has embraced our pyrophosphatase and our RNA enzymes portfolio,” said Jesus C. Morales, business development manager, Canvax, in the release.

Source: Canvax

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Related Content